Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBet v 1-FV immunotherapy for birch pollen allergy
NCT00309062Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Dec 2003
- Primary completion
- Jun 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant Bet v 1 in birch pollen allergy, sponsored by Allergopharma. Started Dec 2003; status: completed.
02
Drugs
recombinant Bet v 1
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT00309062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309062.